Holen Sie sich die Stockscreener-App
4.66
4.48%
0.20
Vorhandelsmarkt:
4.60
-0.06
-1.29%
Schlusskurs vom Vortag:
$4.46
Offen:
$4.5
24-Stunden-Volumen:
2.41M
Relative Volume:
1.10
Marktkapitalisierung:
$780.00M
Einnahmen:
$25.55M
Nettoeinkommen (Verlust:
$-341.97M
KGV:
-1.6643
EPS:
-2.8
Netto-Cashflow:
$-304.44M
1W Leistung:
+7.25%
1M Leistung:
+12.02%
6M Leistung:
-45.81%
1J Leistung:
-54.22%
1-Tages-Spanne:
$4.35
$4.67
1-Wochen-Bereich:
$3.50
$4.67
52-Wochen-Spanne:
$3.50
$11.16
Relay Therapeutics Inc Stock (RLAY) Company Profile
Firmenname
Relay Therapeutics Inc
Sektor
Branche
Telefon
617-370-8837
Adresse
399 BINNEY STREET, CAMBRIDGE
Vergleichen Sie RLAY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
4.66 | 780.00M | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-10 | Fortgesetzt | Goldman | Buy |
| 2024-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-05-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-04-20 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-04-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | Eingeleitet | Raymond James | Outperform |
| 2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
| 2022-09-30 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-02 | Eingeleitet | Stifel | Buy |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-02-01 | Eingeleitet | Berenberg | Buy |
| 2021-07-21 | Eingeleitet | BofA Securities | Buy |
| 2020-12-15 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-11-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-10 | Eingeleitet | Cowen | Outperform |
| 2020-08-10 | Eingeleitet | Goldman | Buy |
| 2020-08-10 | Eingeleitet | Guggenheim | Buy |
| 2020-08-10 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten
Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week LowShould You Sell? - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Short Interest Update - MarketBeat
Relay Therapeutics' SWOT analysis: stock poised for growth amid fierce competition - MSN
Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.8%Time to Sell? - MarketBeat
We're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate - Yahoo Finance
Relay Therapeutics’ (RLAY) Buy Rating Reiterated at HC Wainwright - Defense World
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Relay Therapeutics (NASDAQ:RLAY) Hits New 52-Week LowShould You Sell? - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Given "Buy" Rating at HC Wainwright - MarketBeat
Relay Therapeutics Highlights Progress at Healthcare Conference - TipRanks
Barclays PLC Grows Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Barclays PLC Purchases 136,541 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics seesaws - MSN
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Relay Therapeutics stock hits 52-week low at $4 By Investing.com - Investing.com South Africa
Relay Therapeutics (NASDAQ:RLAY) Hits New 12-Month LowShould You Sell? - MarketBeat
Relay Therapeutics stock hits 52-week low at $4 - Investing.com India
Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics seesaws (LLY:NYSE) - Seeking Alpha
Relay Therapeutics Chief Corporate Development Officer Peter Rahmer Sells 63% Of Holding - Simply Wall St
Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 4.8%Should You Buy? - MarketBeat
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Relay Therapeutics officer sells shares worth $345,571 By Investing.com - Investing.com Australia
Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Sells $73,763.20 in Stock - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Peter Rahmer Sells 32,156 Shares - MarketBeat
Relay Therapeutics officer sells shares worth $345,571 - Investing.com India
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by JPMorgan Chase & Co. - Defense World
JPMorgan Chase & Co. Grows Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics' chief corporate development officer sells $1,752 in stock - Investing.com India
Relay Therapeutics stock hits 52-week low at $4.11 amid market challenges - Investing.com Australia
Relay Therapeutics president sells shares for $2,877 By Investing.com - Investing.com Australia
Relay Therapeutics’ chief corporate development officer sells $1,752 in stock By Investing.com - Investing.com Nigeria
Relay Therapeutics' chief corporate development officer sells $1,752 in stock By Investing.com - Investing.com Australia
Relay Therapeutics president sells shares for $2,877 - Investing.com India
Relay Therapeutics chief legal officer sells $1,309 in stock By Investing.com - Investing.com Nigeria
Relay Therapeutics chief legal officer sells $1,309 in stock - Investing.com India
Thomas Catinazzo Sells 4,865 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock - MarketBeat
Relay Therapeutics CFO sells $21,490 in stock By Investing.com - Investing.com Nigeria
Relay Therapeutics CFO sells $21,490 in stock - Investing.com
Finanzdaten der Relay Therapeutics Inc-Aktie (RLAY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Relay Therapeutics Inc-Aktie (RLAY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Rahmer Peter | See remarks |
Jan 03 '25 |
Sale |
4.30 |
32,177 |
138,361 |
325,330 |
| Rahmer Peter | See remarks |
Jan 02 '25 |
Sale |
4.15 |
32,156 |
133,447 |
357,507 |
| Rahmer Peter | See remarks |
Jan 06 '25 |
Sale |
4.45 |
16,576 |
73,763 |
308,754 |
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):